http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006146939-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2005-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006146939-A |
| titleOfInvention | METHOD FOR TREATING A RING GRANULEM OR A SARCOID |
| abstract | 1. A method of alleviating the course of a annular granuloma or sarcoid disease, comprising administering to a patient having the disease a therapeutically effective amount of an LFA-1.2 antagonist. The method according to claim 1, wherein the annular granuloma is selected from the group consisting of localized, disseminated (generalized), subcutaneous and perforating types of disease. The method of claim 2, wherein the annular granuloma is a disseminated annular granuloma. The method according to any one of the preceding paragraphs, where the LFA-1 antagonist is an anti-LFA-1.5 antibody. The method according to claims 1-3, wherein the LFA-1 antagonist is an anti-ICAM-1.6 antibody. The method of claim 4, wherein the anti-LFA-1 antibody is an anti-CD11a antibody. The method of claim 6, wherein the anti-CD11a antibody is efalizumab. The method according to claim 7, wherein the antibody is administered in a dosage of 0.3 to 4 mg / kg. The method of claim 8, wherein the antibody is administered at a dose of 1 mg / kg / week. The method of claim 8, wherein the antibody is administered at a dose of 2 mg / kg / week. The method of claim 8 or 9, wherein the antibody is administered to the patient in an initial conditioning dose before the therapeutic dose. The method of claim 11, wherein the conditioning dose is 0.7 mg / kg. The method of claim 7, wherein the antibody is administered in an initial conditioning dose of 0.7 mg / kg during the first week, followed by a dose of 1 mg / kg / week for at least 4 weeks. The method of claim 13, wherein a dose of 1 mg / kg is administered for at least 11 weeks. The method of claim 1, wherein the LFA-1 antagonist is administered subcutaneously. The method according to any one of claims 9, 10, 14, wherein the LFA-1 antagonist is administered subcutaneously. The method of claim 1, wherein the LFA-1 antagonist is administered intravenously. 18. The method according to claim 1 or 7, where the LFA-1 antagonist is introduced into |
| priorityDate | 2004-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.